# Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

> **NCT04040205** · PHASE2 · RECRUITING · sponsor: **Medical College of Wisconsin** · enrollment: 44 (estimated)

## Conditions studied

- Chondrosarcoma
- Osteosarcoma
- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT04040205
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-07
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04040205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04040205, "Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04040205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*